Today, Biocartis, an innovative molecular diagnostics company, and Discovery Life Sciences (“Discovery”), a global leader in biomarker specialty laboratory services and biospecimen solutions, are pleased to announce a strategic collaboration to deliver seamless, end-to-end precision oncology solutions to pharmaceutical and biotech customers worldwide.

CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy today announced the successful completion of its previously announced acquisition of Naveris, following the satisfaction of all closing conditions. The transaction terms were disclosed at the time of announcement in April 2026.

Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next-generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2026.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that its Personalis EDTA Blood Collection Kit and Personalis cfDNA Blood Collection Kit have obtained Class A CE-IVD marking in compliance with the European Union’s In Vitro Diagnostic Regulation (IVDR).

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2026.

CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it has entered into a definitive agreement to acquire Naveris, a commercial stage precision oncology diagnostics company with a highly differentiated and Medicare-reimbursed, blood‑based monitoring solution for viral‑mediated cancers. The transaction is an extension of CareDx’s strategy to focus on its U.S. Precision Medicine Testing Services and Patient and Digital Solutions. The definitive agreement provides for an up-front cash consideration of $160 million with up to an additional $100 million based on the achievement of revenue milestones.

Illumina, Inc. (NASDAQ: ILMN) and Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration to advance precision oncology through innovative applications of next-generation sequencing (NGS) solutions across the healthcare ecosystem. Projects are expected to include promoting equitable access to cancer biomarker testing by bringing it closer to patients through new distributed test offerings; generating evidence to facilitate payer coverage; and developing new tests to address areas of unmet need.

Abbott (NYSE: ABT), the global healthcare company, and Flatiron Health, a leading healthtech company advancing point-of-care solutions in oncology, today announced the integration of Abbott’s comprehensive Precision Oncology portfolio into OncoEMR®, Flatiron’s cloud-based Electronic Medical Record (EMR) platform.

BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced a collaboration with Epic, the nation's most widely used comprehensive electronic health record (EHR). The agreement, signed in December 2025, will integrate BillionToOne's prenatal and oncology testing portfolio with Epic's Aura diagnostics suite.

GenomOncology (GO), a leader in precision medicine reporting solutions, today announced a strategic partnership with Oregon Health & Science University's (OHSU) Knight Diagnostics Lab (KDL) to enhance clinical trial matching for cancer patients. Through this collaboration, KDL will implement GO's Clinical Trials Matching Solution to streamline the identification of relevant precision oncology trials and improve patient access to trials and treatment options.